TScan Therapeutics在推进其核心候选药物Tsc-101的临床开发方面取得关键进展。公司宣布，计划于本月内启动针对该药物的三期Alloha-2临床试验，并完成首位患者的入组工作。
这项名为Alloha-2的研究是Tsc-101开发路径上的重要里程碑。该试验旨在进一步评估Tsc-101在特定适应症中的疗效与安全性。成功启动患者入组标志着公司临床运营按既定时间表顺利推进，也意味着其管线资产向潜在商业化目标又迈出了实质性的一步。
市场密切关注TScan Therapeutics的临床进展，此次三期试验的启动被视为公司兑现其研发承诺的关键节点。后续的患者招募速度、试验数据读出时间以及最终结果，都将对公司未来的发展前景产生重要影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.